However, NASH has been shown to limit antitumor surveillance in immunotherapy-treated (via anti-PD1 or anti-PD-L1 treatment) HCC, probably due to NASH-related aberrant CD8+PD1+ T cell activation, rather than tissue damage, leading to impaired immune surveillance [88]. This evidence concerns the gene CD274 and metabolic dysfunction-associated steatohepatitis.